Clinical Trial Search

Primary: The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) — 0.09; 0.17; 0.01 Liter — p=0.022

Primary: Change in Pulmonary Asthma Score (PAS) — 0.9; 0.4 mean PAS score

Primary: %FEV1 — 20; 34; 26; 31 %-predicted

Primary: Symptom Days — 6.24; 4.82 symptom days over past 14 days — p=0.06

Primary: Percentage Change in Mean of Peak Expiratory Flow Rate (PEFR) Percentage of Predicted Baseline at 30 Minutes After the Initial Bronchodilator Treatment — 18.1; 12.9…

Primary: Change From Baseline in Forced Expiratory Volume in One Second (FEV1) Within the First 60 Minutes After Administration — 0.07; 0.05; 0.06 Liter — p=0.871

Primary: Patients Hospitalization Rate — 82; 75 participants

Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510

Primary: Change in Percent of Predicted Peak Expiratory Flow Rate (PEFR) at t15 — 59.56; 52.45 percentage of predicted

Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale

Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2

Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8

Primary: Number of Participants With Bronchodilation — 74; 67 Participants

Primary: Number of Participants With 1 or More Severe Asthma Exacerbations — 186; 154 participants — p=0.036

Primary: Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration — 0.08; 0.07 Liters — p=0.775

Primary: Albuterol-induced Change in FEV1 — 0.27; 0.18; 0.32; 0.20 liters

Primary: Hospital Admission — 57; 208 Participants

Primary: Length of Stay — 2.9; 2.9 days — p=0.632

Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage

Primary: Maximum Change From Baseline in Airway Blood Flow (Qaw) — -11.0; 14.1; 23.9; 25.5 change from baseline ( µl/min/ml) — p=< 0.001

Primary: Number of Subjects With Serious Adverse Events — 0; 0 participants

Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days

Primary: Baseline-adjusted FEV1 30 Minutes After Each Cumulative Dose — 0.421; 0.488; 0.548; 0.586 Liter

Primary: Number of Inhaled Corticosteroid (ICS) Prescriptions Refilled (Confirmed by Primary Care Physician) — 18; 32 Participants — p=0.87

Primary: Asthma Control as Measured by the Asthma Control Test (ACT) — 18.77; 18.96; 20.45; 20.14 units on a scale

Primary: Participants Experiencing an Asthma Exacerbation That Requires Systemic Corticosteroid Therapy — 22; 20; 25; 36 participants — p=0.066

Primary: Number of Participants to Whom an AAP (Asthma Action Plan) Was Delivered by the Clinician — 0; 79 Participants

Primary: Safety- Number of Participants With Adverse Events — 10 Participants

Primary: Duration of Continuous Therapy — 18.3; 16 Hours

Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L